Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Arrhythmias

  Free Subscription


Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 37 articles:
HTML format



Single Articles


    October 2022
  1. BERNARDI M, Spadafora L, Biondi-Zoccai G
    Should we consider recombinant human brain natriuretic peptide to prevent post-operative atrial fibrillation?
    J Cardiovasc Pharmacol. 2022 Oct 10. pii: 00005344-990000000-00120.
    PubMed    


  2. PILOTE S, Simard C, Drolet B
    Remdesivir (VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects.
    J Cardiovasc Pharmacol. 2022;80:616-622.
    PubMed     Abstract available


  3. ESSA H, Dobson R, Lip GYH
    Chemotherapy-Induced Arrhythmias.
    J Cardiovasc Pharmacol. 2022;80:531-539.
    PubMed     Abstract available


    September 2022
  4. MASTER YW, Master QZ, Master HC, Master ZW, et al
    Effects of recombinant human brain natriuretic peptide on atrial fibrillation after coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2022 Sep 9. pii: 00005344-990000000-00114.
    PubMed     Abstract available


    August 2022
  5. GAO H, Li Y, Sun H, Huang X, et al
    Trough Concentration Deficiency of Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00103.
    PubMed     Abstract available


  6. CATURANO A, Spiezia S, Brunelli V, Galiero R, et al
    Polypharmacy and major adverse events in atrial fibrillation.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00109.
    PubMed     Abstract available


  7. YAN J, Ai X
    Holiday Heart Syndrome, Atrial Fibrillation, and RyR2 antagonist.
    J Cardiovasc Pharmacol. 2022 Aug 10. pii: 00005344-990000000-00092.
    PubMed     Abstract available


  8. GRECO LV, Migirov A, Ojamaa K, Li Y, et al
    Stabilizing Cardiac Ryanodine Receptor with Dantrolene Treatment Prevents Binge Alcohol Enhanced Atrial Fibrillation in Rats.
    J Cardiovasc Pharmacol. 2022 Aug 9. pii: 00005344-990000000-00090.
    PubMed     Abstract available


  9. TUNCTAN B, Senol SP, Temiz-Resitoglu M, Yilmaz DE, et al
    Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock.
    J Cardiovasc Pharmacol. 2022;80:276-293.
    PubMed     Abstract available


    July 2022
  10. TSAGKARIS C, Papazoglou AS, Kartas A, Samaras A, et al
    Polypharmacy and major adverse events in atrial fibrillation.
    J Cardiovasc Pharmacol. 2022 Jul 29. pii: 00005344-990000000-00089.
    PubMed     Abstract available


    June 2022
  11. HOSSEINI SH, Talasaz AH, Alidoosti M, Tajdini M, et al
    Pre-Procedural Colchicine in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: a Randomized Controlled Trial (PodCAST-PCI).
    J Cardiovasc Pharmacol. 2022 Jun 22. pii: 00005344-990000000-00067.
    PubMed     Abstract available


  12. CHEN Y, Zhu M, Wang K, Xu Q, et al
    Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombus: An Updated Meta-Analysis of Cohort Studies and Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022;79:935-940.
    PubMed     Abstract available


    May 2022
  13. CARNEVALE R, Biondi-Zoccai G, Giordano A, Pastori D, et al
    From the dining room to the atrium: can we modulate atrial fibrillation risk with micronutrients?
    J Cardiovasc Pharmacol. 2022 May 20. pii: 00005344-990000000-00057.
    PubMed    


  14. OLIVERI F, Bongiorno A, Compagnoni S, Fasolino A, et al
    Statin and Post-Cardiac Surgery Atrial Fibrillation Prevention: Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2022 May 11. pii: 00005344-990000000-00049.
    PubMed     Abstract available


  15. PETERSEN J, Castro L, Bengaard AKP, Pecha S, et al
    Muscarinic Receptor Activation Reduces Force and Arrhythmias in Human Atria Independent of IK,ACh.
    J Cardiovasc Pharmacol. 2022;79:678-686.
    PubMed     Abstract available


    April 2022
  16. RUSSO V, Ammendola E, Gasperetti A, Bottino R, et al
    Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients.
    J Cardiovasc Pharmacol. 2022;79:472-478.
    PubMed     Abstract available


    March 2022
  17. HUANG J
    Circulating concentrations of nutrition-related factors are not causally associated with atrial fibrillation: a Mendelian randomization study.
    J Cardiovasc Pharmacol. 2022 Mar 25. pii: 00005344-990000000-00012.
    PubMed     Abstract available


    February 2022
  18. LAM JC, Stevenson B, Lee YG, Maurer J, et al
    Intravenous to oral transition of amiodarone (IOTA): effect of various durations of overlap on atrial fibrillation recurrence post cardiothoracic surgery.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98047.
    PubMed     Abstract available


    January 2022
  19. ZOU HT, Yang GH, Cai YJ, Chen H, et al
    Are high- or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98061.
    PubMed     Abstract available


    December 2021
  20. WANG Z, Wang W, Li H, Zhang A, et al
    Ivabradine and Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Dec 27. pii: 00005344-900000000-98065.
    PubMed     Abstract available


  21. LI W, Chen X, Xie X, Xu M, et al
    Comparison of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists for atrial fibrillation in type 2 diabetes mellitus: systematic review with network meta-analysis of randomised controlled trials.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98087.
    PubMed     Abstract available


  22. WANG W, Liu J, Ye H, Wang M, et al
    Effect of Dexmedetomidine on Tachyarrhythmias after Cardiac Surgery: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98086.
    PubMed     Abstract available


    November 2021
  23. ZHENG RJ, Wang Y, Tang JN, Duan JY, et al
    Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2021 Nov 22. pii: 00005344-900000000-98109.
    PubMed     Abstract available


  24. BURASHNIKOV A
    Atrial fibrillation induced by anticancer drugs and underling mechanisms.
    J Cardiovasc Pharmacol. 2021 Nov 17. pii: 00005344-900000000-98110.
    PubMed     Abstract available


  25. HIJAZI Y, Karkabi B, Feldman M, Malca B, et al
    Bridging care transition after hospitalization for atrial fibrillation and coronary interventions.
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98113.
    PubMed     Abstract available


    October 2021
  26. LO CT, Niu F, Fredriks DA, Hui RL, et al
    Evaluation of the effectiveness and safety of Direct Oral Anticoagulants in Elderly Patients with Non-Valvular Atrial Fibrillation who are not Candidates for Warfarin in real world setting.
    J Cardiovasc Pharmacol. 2021 Oct 26. pii: 00005344-900000000-98121.
    PubMed     Abstract available


    August 2021

  27. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience: Erratum.
    J Cardiovasc Pharmacol. 2021;78:330.
    PubMed    


  28. ZHANG M, Wang H, Bie M, Wang X, et al
    Caveolin-1 Deficiency Induces Atrial Fibrosis and Increases Susceptibility to Atrial Fibrillation by the STAT3 Signaling Pathway.
    J Cardiovasc Pharmacol. 2021;78:175-183.
    PubMed     Abstract available


    July 2021
  29. SOLTAN F, Esmaili Dahej M, Yadegari M, Moradi A, et al
    Resveratrol Confers Protection Against Ischemia/Reperfusion Injury by Increase of Angiotensin (1-7) Expression in a Rat Model of Myocardial Hypertrophy.
    J Cardiovasc Pharmacol. 2021;78:e55-e64.
    PubMed     Abstract available


    June 2021
  30. CHARAFEDDINE K, Zakka P, Dargham BB, Abdulhai F, et al
    Potential Biomarkers in Atrial Fibrillation: Insight into their Clinical Significance.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98188.
    PubMed     Abstract available


  31. SKORNOVA I, Samos M, Bolek T, Kamenistakova A, et al
    Direct oral anticoagulants plasma levels in atrial fibrillation patients at the time of bleeding: a pilot prospective study.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98186.
    PubMed     Abstract available


  32. LOU YM, Zheng ZL, Xie LY, Lian JF, et al
    Effects of spironolactone on hypoxia-inducible factor-1alpha in the patients receiving coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98182.
    PubMed     Abstract available


    April 2021
  33. TANNER R, Cronin M, Macken L, Murphy R, et al
    Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
    J Cardiovasc Pharmacol. 2021;77:501-507.
    PubMed     Abstract available


    March 2021
  34. HEIDEMANN J, Tanislav C, Kostev K
    (Absence of) Association Between Non-Vitamin K Antagonist Oral Anticoagulant Therapy and Urinary Tract Infection in Patients with Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2021 Mar 12. pii: 00005344-900000000-98230.
    PubMed     Abstract available


  35. HORTIGON-VINAGRE MP, Zamora V, Burton FL, Smith GL, et al
    The Use of Voltage Sensitive Dye di-4-ANEPPS and Video-Based Contractility Measurements to Assess Drug Effects on Excitation-Contraction Coupling in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    J Cardiovasc Pharmacol. 2021;77:280-290.
    PubMed     Abstract available


    February 2021
  36. ANOUASSI Z, Atallah B, Alsoud LO, El Nekidy W, et al
    Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region.
    J Cardiovasc Pharmacol. 2021;77:182-188.
    PubMed     Abstract available


    July 2020
  37. JIA K, Dai Y, Liu A, Li X, et al
    The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000878.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: